Linsitinib (OSI-906)

目录号:S1091

Linsitinib (OSI-906) Chemical Structure

Molecular Weight(MW): 421.49

Linsitinib (OSI-906)是一种选择性IGF-1R抑制剂,在无细胞试验中IC50为35 nM;对InsR抑制作用适中,IC50为75 nM,对Abl,ALK,BTK,EGFR, FGFR1/2,PKA等没有抑制活性。Phase 3。

规格 价格 库存 购买数量  
RMB 1550.54 现货
RMB 1393.48 现货
RMB 2226.24 现货
RMB 5899.91 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献33篇:

客户使用该产品的4个实验数据:

  • Cancer Res 2013 73, 834-843. Linsitinib (OSI-906) purchased from Selleck.

    OSI-906 prevents the emergence and inhibits growth of established hormone-indendent tumors . A and B, MCF-7 cells were injected s.c. into athymic mice supplemented with 14-day release E2 pellets. Mice with no tumors (A) or bearing tumors ≥ 150 mm3 (B) were randomized to vehicle or OSI-906 (50 mg/kg/day, per os) for 6 weeks. Data are presented as number of tumors formed ; , P = 0.02, Fisher's exact test (A) , or mean tumor volume ± SEM; P < 0.05 versus vehicle, 2-way ANOVA (B). C, tumor-bearing mice from (A) were treated with vehicle or OSI-906 for 3 days. Xenografts were harvested 4 hours after the last dose. Tumor lysates were precipitated with a p-Tyr antibody; p-Tyr pull- downs and tumor lysates were analyzed by immunoblot with the indicated antibodies. D, tumor-bearing mice were imaged before and 4 hours after the initial dose of OSI- 906 by [18 F]FDG -PET. Images from a representative mouse show [18 F]FDG uptake pre- and post–OSI-906 (T-tumor ). Quantification is shown at the bottom.  , P < 0.0001, 2-way ANOVA .

    Cancer Res 2011 71, 6773-84. Linsitinib (OSI-906) purchased from Selleck.

  • (A) MHM cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) or Erlotinib (10 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. EGFR immuno-precipitates were probed with anti-phospho tyrosine antibody. In lanes marked “Serum Starved”, MHM cells were serum starved for 24 hours and stimulated with EGF (10 ng/ml) for 10 minutes. Lysates were collected and immunoblotted with indicated antibodies. (B) OS cell lines and primary OS cells were treated with CP (10 μM) alone, OSI-906 (5 μM) alone or with CP in combination with OSI-906 for 48 hours and whole cell lysates were immunoblotted with the indicated antibodies. (C) MHM and S4 (CP resistant MHM derivatives) cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. (D) IGF1 and IGF2 mRNA levels in untreated cells and cells treated with 10 μM CP for 48 hours were determined by qRT-PCR. The level of each mRNA transcript in untreated cells was considered “1.0” and all the other values were plotted relative to it. Shown are the mean results of three experiments, bars, Standard error (SE).

    Oncotarget, 2016, 7(19):27511-26. Linsitinib (OSI-906) purchased from Selleck.

     

    (A) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024, 1µM PPP or 1µM linsitinib for 24h and cell survival was determined by flow cytometry. Results are shown as mean  ± SEM, n=20. (B)CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024 (AG) or 1µM linsitinib (L) and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=6). (C) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 1µM PPP and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=4). (D) CLL B cells purified from freshly isolated or freeze-thawed PBMCs from CLL patient samples were treated with 5-15 µM AG1024 and subject to a Western blot analysis using the indicated antibodies. Results are represented as mean±SEM (n=10). Supplementary Figure 1C shows the associated densitometrical analysis after treatment with 15 µM AG1024. (E) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with 10-500nM rhIGF-1 and immunoblotted for the expression of IGF1R, pIGF1R, pAkt, Akt, pERK and Erk. A representative example from four independent experiments is shown.

    Linsitinib (OSI-906) purchased from Selleck.

产品安全说明书

IGF-1R抑制剂选择性比较

生物活性

产品描述 Linsitinib (OSI-906)是一种选择性IGF-1R抑制剂,在无细胞试验中IC50为35 nM;对InsR抑制作用适中,IC50为75 nM,对Abl,ALK,BTK,EGFR, FGFR1/2,PKA等没有抑制活性。Phase 3。
靶点
IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
35 nM 75 nM 75 nM
体外研究

OSI-906 抑制IGF-IR自磷酸化和下游信号蛋白AKT, ERK1/2和S6激酶的激活,IC50为0.028到 0.13 μM。OSI-906通过与C-螺旋相互作用而使靶点蛋白形成中间结构形态。OSI-906作用于肝脏微粒体,具有良好的代谢稳定性。OSI-906浓度为1μM时,完全抑制IR 和IGF-IR磷酸化。OSI-906抑制一些肿瘤细胞系增殖,包括非小细胞肺癌和结肠直肠癌(CRC)肿瘤细胞系,EC50为0.021到 0.810 μM。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk NH\aeotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLDeY5{UUN3ME2wMlAzQDB4IN88US=> NX\CZ|ZJW0GQR1XS
KS-1 NFO1UWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTBwMEO4N|Uh|ryP M2G2ZXNCVkeHUh?=
TE-11 NUjrOGVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwMEe4NlIh|ryP NVPCRXduW0GQR1XS
EW-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTBwMEi1PFUh|ryP M1PBe3NCVkeHUh?=
HMV-II NWjyNWNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDrZWdHUUN3ME2wMlA5QDR4IN88US=> MlP1V2FPT0WU
COLO-205 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTBwMUC0OVQh|ryP M{XiVnNCVkeHUh?=
ES1 MljXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4j3O2lEPTB;MD6xNFY6PiEQvF2= NXnTbmF1W0GQR1XS
GDM-1 M4e4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TZ[2lEPTB;MD6xN|Y4OiEQvF2= MkDTV2FPT0WU
ML-2 NWTSUmRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTBwMUW4PVYh|ryP MlnoV2FPT0WU
Saos-2 NIPqNZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2GwV2lEPTB;MD6xOlUzPiEQvF2= Mlz0V2FPT0WU
NCI-H1355 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTzVG9KSzVyPUCuNVgyOzVizszN NXrLd4V7W0GQR1XS
G-401 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFyzfIRKSzVyPUCuNVgzOyEQvF2= MWnTRW5ITVJ?
EW-16 NGfCNmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnXW4pKSzVyPUCuNVg4PzdizszN NVXq[YlWW0GQR1XS
EW-7 NHe1UJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwMUi4PFEh|ryP NHTNepJUSU6JRWK=
NCI-H727 NYrV[IVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnFbIRSUUN3ME2wMlE6Pzl2IN88US=> NUHZdZJIW0GQR1XS
LCLC-97TM1 MnjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPuVGs2UUN3ME2wMlIxQTV3IN88US=> NILpU4ZUSU6JRWK=
NCI-H650 NX\rbFJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwMkGzPFQh|ryP MmXQV2FPT0WU
NCI-H2122 Mmm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkm2TWM2OD1yLkKzNlk6KM7:TR?= NFLyR2lUSU6JRWK=
SK-N-DZ MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYe5NIV2UUN3ME2wMlI{Pjl6IN88US=> MknpV2FPT0WU
HT-29 MoK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVj1TWtQUUN3ME2wMlI1OjR6IN88US=> NGTubGtUSU6JRWK=
LB771-HNC NWDYN4pzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwMkW5NVUh|ryP NYi4NXpGW0GQR1XS
HT-144 NUC4VZV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zDN2lEPTB;MD6yOlE6OSEQvF2= NVPYeZA2W0GQR1XS
LAN-6 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmWxTWM2OD1yLkK2N|Q5KM7:TR?= M4LITnNCVkeHUh?=
EW-18 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3WU45KSzVyPUCuNlcxODFizszN NX3FNoZpW0GQR1XS
LS-1034 M3rIXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTBwMkexN|Ih|ryP NGPDR|RUSU6JRWK=
EW-11 NYrSXZgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17SVGlEPTB;MD6yPFQ{OiEQvF2= Mk[0V2FPT0WU
SNU-C1 MknES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzjTWM2OD1yLkK5N|E{KM7:TR?= NXjGblZCW0GQR1XS
RS4-11 NVmzT2JVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LmcmlEPTB;MD6zN|c2QCEQvF2= MnS5V2FPT0WU
ES4 NVvodnE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUSyZlB1UUN3ME2wMlQyODN6IN88US=> MV\TRW5ITVJ?
COLO-320-HSR M3XPU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPpTWM2OD1yLkSxN|Y5KM7:TR?= NF\BUJpUSU6JRWK=
NB10 M2rNUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTBwNEW0N|ch|ryP Ml7SV2FPT0WU
BFTC-905 NH:xT3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnTd3JKSzVyPUCuOFY4PThizszN NXzFRpdqW0GQR1XS
A375 NILQXVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVX6PFFKUUN3ME2wMlQ4PjF5IN88US=> MXfTRW5ITVJ?
SJRH30 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvXTWM2OD1yLkWwPFIzKM7:TR?= MYXTRW5ITVJ?
NOS-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzTTWM2OD1yLkWyNlY4KM7:TR?= NFPYeoNUSU6JRWK=
SIG-M5 NIj1W4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\WUpZrUUN3ME2wMlU{PTV5IN88US=> M1PnUHNCVkeHUh?=
DOK NXHPXXJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEn6SlJKSzVyPUCuOVU3KM7:TR?= MnnwV2FPT0WU
NB69 NFnUU5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonqTWM2OD1yLkW4NlU4KM7:TR?= M1HTSHNCVkeHUh?=
SK-NEP-1 NV3xVmtyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwNkCyN|Yh|ryP NUX6cYNEW0GQR1XS
SK-MM-2 NYTocFh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknJTWM2OD1yLk[1OFkyKM7:TR?= NV\4eo9zW0GQR1XS
NCI-H358 M4fpVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLaTWM2OD1yLk[3NFgzKM7:TR?= MVvTRW5ITVJ?
RH-1 M1\wWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;2b2lEPTB;MD63OFg2QSEQvF2= M2OxbHNCVkeHUh?=
NH-12 M2ftS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXITWM2OD1yLke2NFQ3KM7:TR?= NInm[I1USU6JRWK=
TE-12 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTBwN{[0PFYh|ryP M{HqWXNCVkeHUh?=
COLO-668 MmntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfDc4xtUUN3ME2wMlg1PjZ4IN88US=> M4\6S3NCVkeHUh?=
PANC-08-13 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwOE[zO|ch|ryP NXPuUHBJW0GQR1XS
HCC2998 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLOTIVKSzVyPUCuPFgzPjNizszN M3j5THNCVkeHUh?=
ABC-1 M3i3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTBwOUCzOVIh|ryP NWq3d4pkW0GQR1XS
ES6 NV3LOIlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrrUHpLUUN3ME2wMlkyODZ4IN88US=> MXrTRW5ITVJ?
SNU-387 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37BcGlEPTB;MD65PVM6OyEQvF2= NIjFXYxUSU6JRWK=
CMK NXG5SGFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwOUm5Nlkh|ryP NUXweGxqW0GQR1XS
SJSA-1 NU\TWJRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTFwMEO2OVMh|ryP NVnIdG94W0GQR1XS
SIMA NW\uWVl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrse217UUN3ME2xMlA3QDJ3IN88US=> MkfPV2FPT0WU
ES3 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrlXVlHUUN3ME2xMlEzOjl5IN88US=> NIPsd2tUSU6JRWK=
IGROV-1 M2SzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTFwMUW0OFQh|ryP M1;MbHNCVkeHUh?=
MEL-JUSO MmWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HxVGlEPTB;MT6xOVc2QSEQvF2= NETYUWJUSU6JRWK=
T84 NUHPbow3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\mc4VKSzVyPUGuNlA6OTRizszN NWixNI85W0GQR1XS
CAL-85-1 MoH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTFwMkOxN|gh|ryP NWPIRZlvW0GQR1XS
RD MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPzTWM2OD1zLkK2OFU2KM7:TR?= NFTaNVJUSU6JRWK=
TE-8 NEnaOolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\WTWM2OD1zLkOxOFYzKM7:TR?= MVnTRW5ITVJ?
L-363 M1rKPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWf4eJk3UUN3ME2xMlM1OjB6IN88US=> NGHlfJNUSU6JRWK=
EKVX NYrHTYU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmKyTWM2OD1zLkO0OVY5KM7:TR?= MWPTRW5ITVJ?
SK-MEL-3 NGnPNolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\z[nhCUUN3ME2xMlQ5PTV4IN88US=> NGnZUXlUSU6JRWK=
TGBC24TKB NVv3clY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIT5dnZKSzVyPUGuOVAyQTNizszN M2\qb3NCVkeHUh?=
NCI-H1770 NE\wWnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrBTWM2OD1zLkWxNVE{KM7:TR?= M2O3eHNCVkeHUh?=
HuH-7 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrQVoFKSzVyPUGuOlAxQThizszN MUjTRW5ITVJ?
HL-60 MlLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTo[5FTUUN3ME2xMlY3QTJ6IN88US=> M{nUbnNCVkeHUh?=
TE-1 NUHIfWRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHwTo9KSzVyPUGuO|A6PDVizszN NIP5d5NUSU6JRWK=
LC-2-ad NWnl[W9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LBU2lEPTB;MT63N|g5PyEQvF2= M2\jcnNCVkeHUh?=
LB647-SCLC MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;nSIVKSzVyPUGuO|Y2QDNizszN MYjTRW5ITVJ?
NCI-H2171 NVKxTXBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmqwTWM2OD1zLke3O|E3KM7:TR?= NInEOFlUSU6JRWK=
SK-PN-DW MlPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoGwTWM2OD1zLkmxNlk5KM7:TR?= MnnSV2FPT0WU
MC-IXC NVfie2dtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHVOoZKSzVyPUGuPVg6QCEQvF2= NWjxc3diW0GQR1XS
LS-513 NEnkcGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PRT2lEPTB;Mj6wOVMxPSEQvF2= MWHTRW5ITVJ?
EW-3 Mly4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3RWWxKSzVyPUKuNFk5PDRizszN M1u4UHNCVkeHUh?=
OPM-2 M4LYVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfFTWM2OD1{LkGwNkDPxE1? NYfO[GhrW0GQR1XS
LP-1 M1S0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrjNXRKSzVyPUKuNlU5ODdizszN MlrEV2FPT0WU
LU-134-A NVjEOIdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTJwMke3JO69VQ>? M2\zV3NCVkeHUh?=
CP66-MEL NHryXJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTJwMkmwNVQh|ryP NE\YN4NUSU6JRWK=
HCC1143 M1XrRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHCdXlKSzVyPUKuOFU{PjhizszN MlLWV2FPT0WU
LOXIMVI NUC1W49mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rVcWlEPTB;Mj62NFIyKM7:TR?= MmLMV2FPT0WU
TE-10 Mn70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPoUlV3UUN3ME2yMlcxQDN6IN88US=> Mlq1V2FPT0WU
NCI-H1882 NGfjN|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTJwN{WyNlch|ryP MWLTRW5ITVJ?
CHP-126 NVuzeVNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjE[otKSzVyPUKuO|Y{OTdizszN MYnTRW5ITVJ?
NCI-H1623 M3fjNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTJwOUKwNlQh|ryP MXrTRW5ITVJ?
GB-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPyUWRKSzVyPUKuPVM1ODRizszN NW\KWGdEW0GQR1XS
RCC10RGB M2rNR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1G0dWlEPTB;Mj65OVI5OSEQvF2= M1\EXXNCVkeHUh?=
NCI-H2141 NH[4U5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIe0dmJKSzVyPUKuPVY5QTZizszN NFywPIJUSU6JRWK=
GI-ME-N NYL6VXpyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTNwMEC1OlUh|ryP M2LjdXNCVkeHUh?=
NCI-H526 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zPbGlEPTB;Mz6wOFA5PSEQvF2= NHzSUIxUSU6JRWK=
NCI-H747 NYjRUGl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLrUWNKSzVyPUOuNFQ6QTJizszN M4i5VnNCVkeHUh?=
SNU-423 NWHT[Zh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfFTWM2OD1|LkKwN|E{KM7:TR?= NFvWOZJUSU6JRWK=
A427 NVzucGpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nQRmlEPTB;Mz6yOVY6QSEQvF2= M33X[HNCVkeHUh?=
CAL-12T MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELUSJJKSzVyPUOuOFA4OTNizszN NYH4SVdJW0GQR1XS
LU-99A MmDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\hTWM2OD1|LkS3NVA2KM7:TR?= NV;jenhkW0GQR1XS
MS-1 MkHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTNwNUO0Nlkh|ryP NEL1OnFUSU6JRWK=
SK-LU-1 Ml\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjzVFZKSzVyPUOuO|YzQTVizszN MXXTRW5ITVJ?
SW837 M{LWNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPOTWM2OD1|Lke2N|M{KM7:TR?= NYG4UHd3W0GQR1XS
ES8 NUfhZ5g{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4f3R2lEPTB;Mz64N|g4PyEQvF2= NVTzPWp[W0GQR1XS
MZ2-MEL MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XxN2lEPTB;Mz65NlA5PiEQvF2= NYrJfGN5W0GQR1XS
TGW NYjtZ|FPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGKwWHVKSzVyPUSuNFE{OTFizszN Ml;4V2FPT0WU
GP5d NYqwV4hHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonHTWM2OD12LkC1N|YzKM7:TR?= NUfZV5RUW0GQR1XS
BB49-HNC MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTRwMUWyNVMh|ryP MYHTRW5ITVJ?
NB13 NE[4SFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnwTWM2OD12LkK2PFg4KM7:TR?= NEPZTYJUSU6JRWK=
NTERA-S-cl-D1 MlzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojSTWM2OD12LkK4OlE2KM7:TR?= NIPiblJUSU6JRWK=
NCI-H1648 MoKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPETWM2OD12LkK5PFE6KM7:TR?= NFX0VmtUSU6JRWK=
LCLC-103H M3;Ib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHj1VnlKSzVyPUSuN|IyQTVizszN M4TL[nNCVkeHUh?=
LS-411N M1WxPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXu0e49rUUN3ME20MlQ1QDh3IN88US=> M2jQdHNCVkeHUh?=
NCI-H1092 NHXFRWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXo[ZpyUUN3ME20MlQ2Pjh5IN88US=> NEXJOVNUSU6JRWK=
PANC-10-05 NUjofZdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2f3c2lEPTB;ND62PVg1KM7:TR?= MkLKV2FPT0WU
DK-MG MknTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTRwOEC5N|Mh|ryP NYDOSo9GW0GQR1XS
OVCAR-5 NIPMPY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTRwOEGyNlYh|ryP MmjjV2FPT0WU
CAL-39 NXLWXplNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvrW2NKSzVyPUSuPFc3PyEQvF2= NXTkfHJKW0GQR1XS
TE-441-T MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{e1W2lEPTB;ND65NFU{PyEQvF2= NEPoO3FUSU6JRWK=
MOLT-16 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLKeoJSUUN3ME20Mlk2OjV|IN88US=> MWXTRW5ITVJ?
MCF7 MmnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljNTWM2OD13LkG0OVE4KM7:TR?= MnTpV2FPT0WU
CAPAN-1 NVn0OnZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DVUWlEPTB;NT6yOVcxPyEQvF2= M4q1TnNCVkeHUh?=
PSN1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLRTWM2OD13LkK3NlM2KM7:TR?= NVvRc4FlW0GQR1XS
NCI-H292 M{\1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrkTWM2OD13LkOwNFQ1KM7:TR?= M2jYdHNCVkeHUh?=
CPC-N MnjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTVwM{m0NVkh|ryP M3XzfHNCVkeHUh?=
DoTc2-4510 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXBdm9KSzVyPUWuOFU{PzFizszN M1HSR3NCVkeHUh?=
LB1047-RCC NFHq[3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLHTWM2OD13LkW1PVM{KM7:TR?= MWLTRW5ITVJ?
MHH-ES-1 NVPFc|c{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HzUWlEPTB;NT61PVkxPyEQvF2= NGLiZnhUSU6JRWK=
NMC-G1 NWS4WGEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTVwN{CyNlch|ryP NWftcIlVW0GQR1XS
SW1710 M2izUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTVwN{S3OVEh|ryP MlP3V2FPT0WU
YAPC NIjsNm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTVwN{[yNFEh|ryP NVf4PXBkW0GQR1XS
22RV1 NIPmZ|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHsWYdKSzVyPUWuPFAxOTlizszN M{TaR3NCVkeHUh?=
COLO-679 M122Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPu[|hTUUN3ME21Mlg5QTR6IN88US=> NU[2e3BEW0GQR1XS
TCCSUP MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TWW2lEPTB;NT65N|I2QSEQvF2= M1LlW3NCVkeHUh?=
C2BBe1 NX\mbHljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TI[2lEPTB;NT65N|k4KM7:TR?= M4rvV3NCVkeHUh?=
TE-15 MlfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{n2W2lEPTB;Nj6wOlYxPSEQvF2= NHrpZVZUSU6JRWK=
SCLC-21H NUTaV3hMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHuVFkxUUN3ME22MlExQDR|IN88US=> NFGyRW1USU6JRWK=
EoL-1-cell MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHmxZmlKSzVyPU[uNVY2PjNizszN MoC1V2FPT0WU
NKM-1 NHvjbZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrIN2pKSzVyPU[uNVY4OSEQvF2= MWHTRW5ITVJ?
NCI-H1304 NY\vSZdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPkVlNIUUN3ME22MlI4PDJ6IN88US=> M3K0OnNCVkeHUh?=
NB6 NIX1[IxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIT2dJRKSzVyPU[uNlk3OjJizszN MnXHV2FPT0WU
NALM-6 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLnTWM2OD14LkOzNlMh|ryP MkH1V2FPT0WU
NCI-H522 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2C0RWlEPTB;Nj6zN|MxPiEQvF2= NXzRT5o6W0GQR1XS
MV-4-11 NFr3b2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTZwM{ewO|kh|ryP NWjaRpdrW0GQR1XS
LB2241-RCC Mli2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV62SohKUUN3ME22MlM5PjZ5IN88US=> NXLURllQW0GQR1XS
NCI-H1417 M12xOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzYPFNKSzVyPU[uOFA5PDdizszN NYfZW3hJW0GQR1XS
HT-1197 M3LmXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DKRmlEPTB;Nj61O|EzOiEQvF2= MmPSV2FPT0WU
P30-OHK M{XZSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTZwNkK3O{DPxE1? MkLlV2FPT0WU
ALL-PO MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rlfWlEPTB;Nj63NVkyPiEQvF2= M4nrOHNCVkeHUh?=
OVCAR-4 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYX2NGwxUUN3ME22Mlc2PDB3IN88US=> NIrzdGNUSU6JRWK=
HCC2157 NUP1RnB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXUTWM2OD14Lke3OFc2KM7:TR?= MmrrV2FPT0WU
NCI-H838 MoXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTZwOU[0PUDPxE1? M2LZN3NCVkeHUh?=
NCI-H1299 M{DGemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrjOo5KSzVyPU[uPVcxQSEQvF2= MlqwV2FPT0WU
SW954 MlvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTdwMkCwOlgh|ryP MVnTRW5ITVJ?
NCI-H441 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\YTWM2OD15LkO0NFY2KM7:TR?= NW\3WJRiW0GQR1XS
SK-MEL-2 NFLieW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkH2TWM2OD15LkS4N|c{KM7:TR?= M1K2S3NCVkeHUh?=
KARPAS-45 M2\qbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkj5TWM2OD15Lk[1PVI6KM7:TR?= NVz1[2M3W0GQR1XS
CAL-54 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nnfmlEPTB;Nz64Nlk4PyEQvF2= M2XqRXNCVkeHUh?=
KYSE-180 NGTEVJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXC[Jo{UUN3ME23Mlg5QTRzIN88US=> NHv4O2dUSU6JRWK=
NCI-H187 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LiOGlEPTB;Nz65OVk1PyEQvF2= NUfvd5IzW0GQR1XS
RT-112 MoLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjFc3lbUUN3ME24MlA6Pjd5IN88US=> NU[xeosxW0GQR1XS
NCI-H1437 NXzV[JcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjzcGRKSzVyPUiuNFk4QTVizszN NHTSS5JUSU6JRWK=
SNU-449 M4XUcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXy5[IdTUUN3ME24MlI5Ojd{IN88US=> NV\CeW9{W0GQR1XS
HCC1187 NXLVRZdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWKwfVlnUUN3ME24MlI6OzlzIN88US=> NHrySIhUSU6JRWK=
NCI-H2030 NYXObI9iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHz3T|JKSzVyPUiuN|c4OTRizszN MYnTRW5ITVJ?
HuO-3N1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TB[2lEPTB;OD6zO|g1PCEQvF2= MUnTRW5ITVJ?
COLO-792 MnzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;KZYFKSzVyPUiuOFE2OjdizszN MW\TRW5ITVJ?
MIA-PaCa-2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LTO2lEPTB;OD64OVUxQCEQvF2= Mn\HV2FPT0WU
SK-N-FI M3qxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTlwMESyOUDPxE1? NHnO[YtUSU6JRWK=
MMAC-SF M3LRTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTlwMEm3OVEh|ryP MUHTRW5ITVJ?
NCI-H28 M1XCWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDHV2dLUUN3ME25MlExPDZ7IN88US=> MlywV2FPT0WU
ETK-1 NWrxOJNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW[5WnE6UUN3ME25MlI6QTd2IN88US=> NUf3O3Z7W0GQR1XS
NCI-H1993 MmC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTlwNESyOlEh|ryP MnziV2FPT0WU
no-11 NX\QbmU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\PVVRCUUN3ME25MlQ4OTJizszN M{HoenNCVkeHUh?=
ChaGo-K-1 NYTNOIc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTlwNUG1PFMh|ryP M4PoR3NCVkeHUh?=
NCCIT MkXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrOc2hsUUN3ME25MlU{OTZ7IN88US=> MUHTRW5ITVJ?
SAS M3\pcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrWTWM2OD1zMD6yOFgh|ryP M{XOXHNCVkeHUh?=
A673 M3HH[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TuRWlEPTB;MUCuN|cxPCEQvF2= M1jXN3NCVkeHUh?=
NCI-H1522 NUnG[HlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWT5WFZjUUN3ME2xNE4{PzB5IN88US=> MmP1V2FPT0WU
NCI-H810 NFLDXJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PBR2lEPTB;MUCuN|kxPyEQvF2= NVy1cWc3W0GQR1XS
IST-MES1 NFrrTFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrXTWM2OD1zMD60OVY1KM7:TR?= NI[1WIlUSU6JRWK=
GR-ST MkDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnLSYkyUUN3ME2xNE42ODJ2IN88US=> NETa[pJUSU6JRWK=
SUP-T1 NFPhT4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HqPGlEPTB;MUCuO|MyPyEQvF2= Mlf6V2FPT0WU
NB5 NF\RdGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjpSG5LUUN3ME2xNE46ODJ{IN88US=> MnTDV2FPT0WU
MZ1-PC M2fLXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIX6[mRKSzVyPUGwMlk2PzFizszN M1;rUnNCVkeHUh?=
SK-CO-1 MlzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTFyLkm5N|Eh|ryP NHXqO2JUSU6JRWK=
Capan-2 NIjFOHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17N[WlEPTB;MUGuN|E6QCEQvF2= NFy5W5ZUSU6JRWK=
697 NXLQO4RGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fifGlEPTB;MUGuOlc2PyEQvF2= NF3OWXdUSU6JRWK=
REH MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV2xTGNLUUN3ME2xNU44PDVzIN88US=> MnjEV2FPT0WU
GI-1 MnPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPUdWxKSzVyPUGxMlg3OTVizszN NUezTmtQW0GQR1XS
BB65-RCC NHntc2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfKPI9lUUN3ME2xNk4xQTF4IN88US=> MkP1V2FPT0WU
NCI-H1651 M1rlO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\rbGlEPTB;MUKuNlQ4QCEQvF2= NXLjdWc{W0GQR1XS
NCI-H1618 NXnpc3ROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTySnJvUUN3ME2xNk4{QTd4IN88US=> NInFNnhUSU6JRWK=
NCI-H2081 MnvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTF{Lk[xOFEh|ryP MkPVV2FPT0WU
GCIY M{\Fcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTF{LkeyNVMh|ryP MmXXV2FPT0WU
NY NY\EelJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTF|LkC2OFMh|ryP M2DMb3NCVkeHUh?=
PANC-03-27 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fxW2lEPTB;MUOuNFgxPyEQvF2= MUjTRW5ITVJ?
BHY MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17ybGlEPTB;MUOuNlEzOSEQvF2= MYHTRW5ITVJ?
SK-OV-3 M17ueWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTQOVlOUUN3ME2xN{4{PzZ|IN88US=> M1nPRnNCVkeHUh?=
5637 NFTXNmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\kPGlEPTB;MUOuO|c2QSEQvF2= MlTjV2FPT0WU
LC-1F M3;Z[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV2wdHhtUUN3ME2xOE4xOzV4IN88US=> NHvqe5JUSU6JRWK=
SNB75 MkjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fIWGlEPTB;MUSuNFM5OyEQvF2= MlPIV2FPT0WU
CHP-212 MlfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3VTWM2OD1zND6wOFY1KM7:TR?= NIXIcnhUSU6JRWK=
HT-1376 NYDacoVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrYcIFKSzVyPUG0MlEyOjZizszN MVvTRW5ITVJ?
MONO-MAC-6 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnwTWM2OD1zND6xOVAzKM7:TR?= NYDJZpVFW0GQR1XS
CA46 MmfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXOTWM2OD1zND6xPFI4KM7:TR?= NG[1dlZUSU6JRWK=
SCC-15 NIG3WGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3XTWM2OD1zND61OVg{KM7:TR?= NVXSSoZ[W0GQR1XS
ATN-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHWxUIdKSzVyPUG0MlY3OjdizszN M{T1PXNCVkeHUh?=
NCI-H2405 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFz0SVRKSzVyPUG0MlgyPTdizszN M3;IRXNCVkeHUh?=
NCI-H716 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLidJp1UUN3ME2xOE45PDl|IN88US=> M2rxenNCVkeHUh?=
SW620 NVvVUIliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH34epdKSzVyPUG0MlkxOTRizszN M3LodnNCVkeHUh?=
NCI-H226 MnfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HFNmlEPTB;MUSuPVA5PSEQvF2= NILyZ4lUSU6JRWK=
SW962 M3TnbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTF2Lkm0N|Ih|ryP MmDMV2FPT0WU
KYSE-150 M2HOTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHUcFN2UUN3ME2xOE46PTVizszN NULGeFVnW0GQR1XS
OCUB-M M3;Ge2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zFd2lEPTB;MUSuPVg5OyEQvF2= MkH5V2FPT0WU
ES7 Mn7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnReIhKSzVyPUG1MlA6QDRizszN MY\TRW5ITVJ?
SW1463 NHjCbFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml:4TWM2OD1zNT60NlI{KM7:TR?= MYDTRW5ITVJ?
CAKI-1 M37UXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHFTWM2OD1zNT61N|Q3KM7:TR?= NVPUWpc{W0GQR1XS
MKN28 NX7UNY9ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLITWM2OD1zNT61OFc6KM7:TR?= MmTjV2FPT0WU
SW13 MoTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnP1TWM2OD1zNT62NVgh|ryP M1LrVHNCVkeHUh?=
A3-KAW MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjqXmM4UUN3ME2xOU46Pjl5IN88US=> MorLV2FPT0WU
LU-65 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmX1TWM2OD1zNT65O|Y5KM7:TR?= NFWwSnhUSU6JRWK=
Calu-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorETWM2OD1zNj6wN|Y5KM7:TR?= MmjRV2FPT0WU
ST486 NUPDRVVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfMNFdKSzVyPUG2MlA1OzFizszN MnfoV2FPT0WU
BB30-HNC MnLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LBcGlEPTB;MU[uNVI1PiEQvF2= MV;TRW5ITVJ?
EGI-1 NFzmPY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDLWYRKSzVyPUG2MlQ1PiEQvF2= NH;WUpBUSU6JRWK=
SH-4 NHXrdo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTF4LkS3N|Eh|ryP MYfTRW5ITVJ?
MN-60 NIC5VGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoK4TWM2OD1zNz6yNlk4KM7:TR?= NVO3N3lYW0GQR1XS
MPP-89 NIHnWYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLwZ2w6UUN3ME2xO{4zPDV7IN88US=> MVPTRW5ITVJ?
A2780 NXX1PY1JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fid2lEPTB;MUeuOFE{QSEQvF2= NHrKO4JUSU6JRWK=
Daoy NWLyeoxIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfveGpWUUN3ME2xO{41Pjl3IN88US=> MmnPV2FPT0WU
NCI-H2126 MoXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTtTYpxUUN3ME2xO{41PzdzIN88US=> NV;jRYFYW0GQR1XS
NCI-H1563 MlrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1mybGlEPTB;MUeuOFkyPyEQvF2= MU\TRW5ITVJ?
8-MG-BA MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUH3VotZUUN3ME2xO{43PjR6IN88US=> NFPtXnBUSU6JRWK=
786-0 M3vVUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTF5LkizOVMh|ryP NF7Q[2FUSU6JRWK=
AM-38 M1OzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYG0[4xEUUN3ME2xO{46OzB4IN88US=> MoDpV2FPT0WU
COLO-824 NXjE[|RjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\ZTWM2OD1zOD60OFM3KM7:TR?= NFzrS4NUSU6JRWK=
SK-MEL-30 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWn1fJBwUUN3ME2xPE42ODh{IN88US=> M2i0[nNCVkeHUh?=
CESS Mmm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XaZ2lEPTB;MUiuO|YxQSEQvF2= NEDTb3BUSU6JRWK=
BL-70 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfLT3dKSzVyPUG4MlgyPTZizszN MVrTRW5ITVJ?
NCI-H2170 NHfM[lNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTF6LkmxO|kh|ryP NGPvSpRUSU6JRWK=
HT-3 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTF6Lkm4N{DPxE1? Mof2V2FPT0WU
BOKU NULNNWdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHOzcZZKSzVyPUG5MlA{QDFizszN MWrTRW5ITVJ?
HPAF-II MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoOxTWM2OD1zOT6zNFE2KM7:TR?= MlHuV2FPT0WU
KGN MoD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jUTWlEPTB;MUmuOFc3PSEQvF2= M3:5[nNCVkeHUh?=
MC-CAR NHTiSYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3OTWM2OD1zOT62N|E{KM7:TR?= NIDLVFJUSU6JRWK=
BHT-101 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTF7Lke3O{DPxE1? M{DxOXNCVkeHUh?=
SW1783 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInCZm5KSzVyPUG5Mlc5ODZizszN NYmwbXNNW0GQR1XS
KP-N-YN MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fPTmlEPTB;MkCuNFI3OiEQvF2= NELiVXpUSU6JRWK=
LU-165 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHraNVdKSzVyPUKwMlU2PzFizszN M3HMUnNCVkeHUh?=
GOTO NHPNOWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELW[YFKSzVyPUKwMlY1PTFizszN MkHXV2FPT0WU
EFM-19 MlrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml:yTWM2OD1{MT6wO|E3KM7:TR?= MmLGV2FPT0WU
CTV-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzxTVNKSzVyPUKxMlExPTRizszN M3PJcXNCVkeHUh?=
HEL NFn4eWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nmVGlEPTB;MkGuOFIyPiEQvF2= MlLmV2FPT0WU
SNU-C2B MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTJzLkSyOkDPxE1? NEXtPGVUSU6JRWK=
ECC4 MmLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;UPZdUUUN3ME2yNU44ODdizszN NIH3dXlUSU6JRWK=
NEC8 NIC3[JZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3JN2dVUUN3ME2yNU45OzZ6IN88US=> M1\3eHNCVkeHUh?=
KMOE-2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPxN3lKSzVyPUKxMlg6OjFizszN MkPEV2FPT0WU
NCI-H524 M2rzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\zUmlEPTB;MkKuNFgxQCEQvF2= MV;TRW5ITVJ?
WSU-NHL MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX76Z4p1UUN3ME2yNk4yPTd5IN88US=> M{LoWnNCVkeHUh?=
SF126 NHe2SJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPlUmJwUUN3ME2yNk4zPDZ7IN88US=> NGX0VGRUSU6JRWK=
HOP-92 M{TDfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPTTWM2OD1{Mj6zNVY4KM7:TR?= M4TMUHNCVkeHUh?=
CTB-1 NEKwWmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTJ{LkS2O|ch|ryP M3zoNnNCVkeHUh?=
KYSE-270 NV65OYpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXS3XYg6UUN3ME2yNk46OzV5IN88US=> NFn2WYxUSU6JRWK=
SK-MEL-24 Mlv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\QTWM2OD1{Mz6xPFch|ryP M2n2WXNCVkeHUh?=
Calu-3 NXzRWmZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTCTWFKUUN3ME2yN{4zOTJ6IN88US=> MYDTRW5ITVJ?
GAMG M3nmS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXhOpdKSzVyPUKzMlI{PjdizszN MkPyV2FPT0WU
SW1573 NVvycZRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnyfpVKSzVyPUKzMlc1OTVizszN M4XnNXNCVkeHUh?=
MHH-NB-11 Mn;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTJ2LkCxPVQh|ryP NXLSV4oxW0GQR1XS
TK10 MknTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLqSY42UUN3ME2yOE42ODF|IN88US=> NIjHTlFUSU6JRWK=
LB373-MEL-D MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7U[nk{UUN3ME2yOE43ODZ2IN88US=> NF\IWmdUSU6JRWK=
KALS-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXP6[lNJUUN3ME2yOE44OzJ5IN88US=> NFnlNY9USU6JRWK=
HUTU-80 MmPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHKTWM2OD1{NT64NFMzKM7:TR?= NEP5WVNUSU6JRWK=
HuP-T3 NEjtXmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTJ4LkG2O|Qh|ryP NXjiU483W0GQR1XS
OE19 NFPidplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnv0TWM2OD1{Nj6yNVU{KM7:TR?= Mn7OV2FPT0WU
J82 NXTlNoFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjoPYtvUUN3ME2yOk4zPDdzIN88US=> Mo\NV2FPT0WU
DU-4475 NXi2WXV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TQdWlEPTB;Mk[uN|gyQSEQvF2= MW\TRW5ITVJ?
DMS-53 NVq2SIJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\wZnRKSzVyPUK2MlUyOzhizszN MnTYV2FPT0WU
COLO-741 MnjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvYUmNKSzVyPUK2Mlg{PDRizszN M4LOUnNCVkeHUh?=
SW48 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTnc3lKSzVyPUK2Mlg5OiEQvF2= MmrtV2FPT0WU
IGR-1 M33wUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTJ4LkmzN|Qh|ryP MXjTRW5ITVJ?
639-V NFG0c5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUe1S49XUUN3ME2yO{4xOjR3IN88US=> Mm\3V2FPT0WU
LK-2 MkjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPvTWM2OD1{Nz60NVQyKM7:TR?= NYL5N4h4W0GQR1XS
NCI-H2347 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXm0dHNmUUN3ME2yO{46Pjl7IN88US=> M324cnNCVkeHUh?=
NCI-H2228 NEjaWIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4m1PGlEPTB;MkiuNFkxPSEQvF2= M1rDfHNCVkeHUh?=
LS-123 NV\NOmJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\hO4pqUUN3ME2yPE4yOjZ{IN88US=> NVrHPZM{W0GQR1XS
U031 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nKV2lEPTB;MkiuNlUzKM7:TR?= M3PTZ3NCVkeHUh?=
NCI-H1792 NX:w[nBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPXbVRKSzVyPUK4MlQ4OjFizszN NEiyfG5USU6JRWK=
NCI-H2087 Ml7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoryTWM2OD1{OD63OVUzKM7:TR?= NVvuXYtQW0GQR1XS
NCI-H2342 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHPdHZKSzVyPUK5MlUzODhizszN NIfte4xUSU6JRWK=
SW626 NHnWUJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XaRmlEPTB;MkmuO|U3KM7:TR?= M4PBUHNCVkeHUh?=
LB2518-MEL M4j5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXsTWM2OD1{OT64NVUh|ryP M3jUSHNCVkeHUh?=
RXF393 MnLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\uU|dKSzVyPUOwMlA6PTJizszN M2G2cnNCVkeHUh?=
LC4-1 MnPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml6zTWM2OD1|MD6zNFkzKM7:TR?= MYfTRW5ITVJ?
NCI-H1694 M1WyWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFKxbWpKSzVyPUOwMlY3OjRizszN Mm\3V2FPT0WU
K5 NULae4FYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jhZmlEPTB;M{CuPVcxOiEQvF2= M3vlcnNCVkeHUh?=
HDLM-2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\GSHBxUUN3ME2zNE46PzJ3IN88US=> MYHTRW5ITVJ?
BCPAP MnHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPvUJdmUUN3ME2zNU45Ozd7IN88US=> Mn\mV2FPT0WU
BC-3 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrqVGxKSzVyPUOyMlE1ODNizszN NXvZS3l1W0GQR1XS
LB996-RCC NY\nNVlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvEd2ZKSzVyPUOyMlI{PThizszN MWDTRW5ITVJ?
NCI-H2009 NILXWmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TnWWlEPTB;M{KuOFk5OSEQvF2= MYnTRW5ITVJ?
HTC-C3 MlXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2m1SGlEPTB;M{OuO|UyQSEQvF2= M1O2SHNCVkeHUh?=
LAMA-84 NEnEZZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrGfGZoUUN3ME2zOE41PDB5IN88US=> MXzTRW5ITVJ?
CCRF-CEM Mo\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknBTWM2OD1|ND61O|E2KM7:TR?= NYPBS2JwW0GQR1XS
AN3-CA M3LMSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfaOWJKSzVyPUO1MlA2PjhizszN MoXzV2FPT0WU
NCI-H1734 NH33NXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4ezRWlEPTB;M{WuNlU3OSEQvF2= MlXaV2FPT0WU
Ca-Ski NFmwemtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTN3LkSxNFEh|ryP NE\JWoNUSU6JRWK=
U-266 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnMU|dKSzVyPUO1MlYyOTRizszN NW\KeoUzW0GQR1XS
SBC-5 NWq3OJVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDDR2FKSzVyPUO1Mlc4QDFizszN MV3TRW5ITVJ?
GT3TKB MlfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTN5LkGxOUDPxE1? M1PC[XNCVkeHUh?=
MDA-MB-175-VII NGXnWZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvmTWM2OD1|Nz6yNlQ5KM7:TR?= M3PMUnNCVkeHUh?=
PFSK-1 NHPZUldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHiye29KSzVyPUO3MlI1OzVizszN MlzzV2FPT0WU
IMR-5 NXHQ[oVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTN5LkK0PFch|ryP NIG5PXRUSU6JRWK=
Daudi M2rFXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHrdVFKSzVyPUO3MlM2QTdizszN M3HKNnNCVkeHUh?=
A498 NHHqW5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTN5LkeyNVgh|ryP NETRbVZUSU6JRWK=
SCC-4 NXHvSpk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXTU3dKSzVyPUO3Mlc5PDNizszN MnXVV2FPT0WU
COLO-680N MlTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHhe5dKSzVyPUO4MlI5QDVizszN MnW0V2FPT0WU
SK-MES-1 MnnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXweJJKSzVyPUO4MlMzOTVizszN MkHMV2FPT0WU
SR MoXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnoV2dKSzVyPUO4MlU1QTVizszN MkjFV2FPT0WU
LNCaP-Clone-FGC Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvQZpB6UUN3ME2zPE42PjN5IN88US=> M1L5S3NCVkeHUh?=
SK-HEP-1 M3G0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7xTWM2OD1|OD63PFIzKM7:TR?= MorMV2FPT0WU
BPH-1 NHvhfJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;iOXdKSzVyPUO4Mlg{OjlizszN M3\5dnNCVkeHUh?=
NCI-H1755 M2S1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHFdpFKSzVyPUO5MlU5OTdizszN MYfTRW5ITVJ?
LXF-289 MkLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\5U2lEPTB;M{muPFA5PCEQvF2= MYTTRW5ITVJ?
SW1088 NE\HOplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTRyLkKxNFch|ryP MoHDV2FPT0WU
MOLT-4 M3n4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLTeFBKSzVyPUSwMlI6ODFizszN M{nEWXNCVkeHUh?=
AsPC-1 M2Dndmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HXXWlEPTB;NECuOFU5OyEQvF2= NF\mVmdUSU6JRWK=
HOP-62 M2XSPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTRyLk[1Olgh|ryP NEXLc25USU6JRWK=
A172 M{TRS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfVe|NKSzVyPUSwMlg2OTFizszN NX7ueIpFW0GQR1XS
SN12C NX;IeopJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\RSodKSzVyPUSwMlk{QDVizszN MmW4V2FPT0WU
MDA-MB-231 NH;UeGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13HUGlEPTB;NECuPVg6QCEQvF2= MkDrV2FPT0WU
RPMI-2650 MnLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHPfGlHUUN3ME20NU4yPTl|IN88US=> NYPndG5[W0GQR1XS
KYSE-140 NHLxSINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7jOG1KSzVyPUSxMlgyOjNizszN NIHtclRUSU6JRWK=
KINGS-1 M1u4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTR{LkS2PVch|ryP NVKzOWhIW0GQR1XS
HSC-3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HScmlEPTB;NEKuOlY3OSEQvF2= M4HINHNCVkeHUh?=
PC-14 M{K4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVyxeZExUUN3ME20N{4yQDh{IN88US=> NED6NodUSU6JRWK=
COR-L105 M4HQSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjGbZdbUUN3ME20N{43PTB{IN88US=> MYnTRW5ITVJ?
BE-13 NYHtfWxsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTR2LkKzO|Eh|ryP MkLzV2FPT0WU
NCI-H661 M2SyWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PQTmlEPTB;NESuNlk2QCEQvF2= NUPUcJNnW0GQR1XS
IST-MEL1 Moq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXrTWM2OD12ND6zOVk6KM7:TR?= MlrMV2FPT0WU
HCC1806 NWnQVmJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzsVnlKSzVyPUS0MlU5PzNizszN NFG1bpBUSU6JRWK=
COLO-800 NFfHOoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjMTWM2OD12ND64OFU{KM7:TR?= MW\TRW5ITVJ?
IST-SL2 NH;UTldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LMXGlEPTB;NEWuNVI1PyEQvF2= MULTRW5ITVJ?
8305C NXXLVJpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGW5e5RKSzVyPUS1MlMxQSEQvF2= MXnTRW5ITVJ?
UACC-62 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jrN2lEPTB;NE[uNlg4PSEQvF2= MWfTRW5ITVJ?
COR-L23 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjaZnlKSzVyPUS3MlE6QSEQvF2= MX7TRW5ITVJ?
EFE-184 M4LCb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTR5LkO4PEDPxE1? NVjjbYd7W0GQR1XS
DMS-114 M2XLTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVu3SWFXUUN3ME20O{41OTR7IN88US=> M1vsWXNCVkeHUh?=
KYSE-520 M2rsXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrESHlKSzVyPUS4MlU{OTVizszN NHfEZYlUSU6JRWK=
SNG-M MlrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7Je|hKSzVyPUS5MlQ{PCEQvF2= M2DQZnNCVkeHUh?=
A2058 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTR7LkS4PFUh|ryP MXLTRW5ITVJ?

... Click to View More Cell Line Experimental Data

体内研究 OSI-906 作用于IGF-IR驱动的移植瘤鼠模型,抑制肿瘤生长,按 75 mg / kg剂量处理,导致100% TGI和 55% 衰退,按25 mg/kg剂量处理,导致 60% TGI,没有衰退。OSI-906处理犬,大鼠和小鼠,诱导不同的消除半衰期,消除半衰期分别为1.18 小时, 2.64小时 和2.14小时。OSI-906按不同剂量单独处理给药雌性Sprague-Dawley 大鼠和雌性CD-1小鼠,每天一次,Vmax值与OSI-906 剂量不成比例。OSI-906 按 25 mg/kg剂量处理12天,提高血糖值。OSI-906按75 mg/kg 剂量单独处理IGF-IR-驱动的人全长人类IGF-IR (LISN)移植鼠模型,在4 和24小时间最大程度抑制IGF-IR磷酸化(80%),血浆药物浓度为26.6-4.77 μM。[1] OSI-906 按60 mg/kg剂量单独作用于NCI-H292 移植鼠,处理2,4,24小时,抑制糖吸收。OSI-906 作用于NCI-H292移植鼠模型,抑制肿瘤生长。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

蛋白激酶生化实验:

通过以ELISA为基础的检测法(IGF-IR, IR, EGFR 和 KDR)或使用100 µM ATP的放射检测法进行蛋白激酶检测实验。在内部ELISA检测实验中,使用聚 (Glu:Tyr)作为底物,结合到96孔实验板表面,使用辣根过氧化物酶标记的自磷酸化抗体测定磷酸化。使用ABTS作为过氧化物酶底物,通过在405/490 nm处测量吸光度而测定结合的抗体。所有实验使用纯化的重组激酶催化域。在昆虫细胞中,人类IGF-IR或EGFR的重组酶表达作为NH2-末端谷胱甘肽S-转移酶融合蛋白,且在内部纯化。通过抑制百分数对log10药品浓度的S型剂量-反应曲线测定IC50值。进行内部实验需重复进行实验,除非另有说明,取三次测量的最小值。
细胞实验:[1]
+ 展开
  • Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 和Hepa-1, RKO 3T3/hulGF-IR, H292 细胞
  • Concentrations: 0.02-0.8 μM
  • Incubation Time: 3天
  • Method: 为了测定细胞增殖,细胞接种在含FCS 10%的合适培养基上,在不同浓度OSI-906存在时,温育3天。通过细胞内ATP含量的荧光量化,使用CellTiterGlo测定抑制细胞生长的情况。数据作为衡量最大增殖的一部分,通过在不同浓度 OSI-906存在时的细胞密度除以对照组(只用DMSO处理)细胞密度。
    (Only for Reference)
动物实验:[1]
+ 展开
  • Animal Models: IGF-IR驱动的全长人类IGF-IR (LISN) 移植小鼠模型
  • Formulation: 25 mM 酒石酸
  • Dosages: 25 mg/kg和75 mg/kg
  • Administration: 口服处理,每天一次,持续14天
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 84 mg/mL (199.29 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
30% PEG 400+0.5% Tween 80+5% Propylene glycol
30mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 421.49
化学式

C26H23N5O

CAS号 867160-71-2
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02057380 Completed Advanced Solid Tumors Astellas Pharma Global Development Inc.|Astellas Pharma Inc April 16 2014 Phase 2
NCT02546544 Completed Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2
NCT01567384 Withdrawn Cancer|Neoplasms|Tumors Emory University|OSI Pharmaceuticals May 2012 Phase 1
NCT01560260 Completed Carney Complex|Chondrosarcoma|Gastrointestinal Stromal Tumor|Paraganglioma National Cancer Institute (NCI) March 2012 Phase 2
NCT01533246 Completed Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer National Cancer Institute (NCI) February 2012 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

  • 回答:

    OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pat